Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Lung Cancer, Non Small Cell Lung Cancer
The Canada Lymph Node Score Project: A Crossover Trial
Before deciding on treatment for patients with lung cancer, a critical step in the investigation is finding out whether the lymph nodes in the chest contain cancer cells.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
- Trial name
- CLNS (NCT04342377)
- Testing
- Selective Targeted Sampling, Systematic Sampling
- Where
- 7 sites in Canada
- Volunteers
- 80 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Nsclc, NSCLC Stage II
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
This research study is being done to find out if a drug called cemiplimab is safe in adult patients who have non-small cell lung cancer (NSCLC) that can be surgically removed (resectable Stage II, IIIA, or select IIIB NSCLC).
- Conditions
- Nsclc, NSCLC Stage II, NSCLC, Stage III, NSCLC Stage IIIB
- Trial name
- NCT07746388
- Testing
- Cemiplimab
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Stage III Non-small-cell Lung Cancer
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Stage III non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of different treatment modalities are not clear.
- Trial name
- NCT04181372
- Testing
- Anlotinib hydrochloride, platinum-based chemotherapy medicine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
NSCLC, Stage III
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
The purpose of this conversion therapy study is to evaluate the safety and efficacy of neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally advanced NSCLC.
- Trial name
- NCT05611879
- Testing
- Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC), Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00729612
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Greg Otterson
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC).
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04310007
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 611 sites in United States
- Volunteers
- 117 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
This phase II trial is studying how well bortezomib works in treating patients with stage IIIB or stage IV lung cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT00118144
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01139944
- Testing
- DNA methylation analysis, polymerase chain reaction, laboratory biomarker analysis
- Volunteers
- 99 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00368992
- Testing
- cetuximab, paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer Stage IV
Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
This is a single arm, open label, Phase II study in KRAS-positive and KRAS-negative patients with stage IV (including pleural effusion) non squamous NSCLC who have failed two lines of anti-cancer therapy.
- Trial name
- NCT02047344
- Testing
- Antroquinonol
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 31 people
- Sponsor
- Golden Biotechnology Corporation
Lung Cancer
Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293332
- Testing
- bevacizumab, carboplatin, docetaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
This trial studies the side effects and how well nintedanib works compared to a placebo in treating against radiation-induced pneumonitis (inflammation of the lungs) in patients with non-small cell lung cancer that cannot be…
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
- Trial name
- NCT02452463
- Testing
- Durvalumab, Nintedanib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma, Non Small Cell Lung
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.
- Trial name
- NCT00160069
- Testing
- Sagopilone (BAY86-5302, ZK 219477)
- Where
- 17 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Bayer
Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
This phase I/II trial studies the best dose and side effects of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and nivolumab and to see how well they work in treating patients with non-small cell lung cancer or…
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive
- Trial name
- NCT02955290
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Roswell Park Cancer Institute
ALK Gene Translocation, EGFR Activating Mutation
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of plinabulin when given together with nivolumab and to see how well they work in treating patients with stage IIIB-IV non-small cell lung cancer that has come back or…
- Conditions
- ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation
- Trial name
- NCT02846792
- Testing
- Nivolumab, Plinabulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Lung Cancer (NSCLC)
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with centrally located early-stage non-small cell lung…
- Trial name
- NCT06730295
- Testing
- Online adaptive SBRT
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
The neoadjuvant Immune Checkpoint Inhibitor (ICI) or ICI combination with chemotherapy for Non-small cell lung cancer (NSCLC) had induced higher major pathologic response (MPR) and complete pathological response (PCR).
- Conditions
- Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, PET/CT
- Trial name
- DYNAPET (NCT04586465)
- Testing
- pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer.
- Trial name
- NCT03137771
- Testing
- 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine
- Where
- 301 sites in United States, Canada and 2 more
- Volunteers
- 218 people
- Sponsor
- NRG Oncology
Non-Small Cell Lung Cancer
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
- Trial name
- CheckMate 955 (NCT03048136)
- Testing
- Nivolumab, Ipilimumab
- Where
- 17 sites in United States, Argentina and 3 more
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.